As costs continue to soar ever higher, AstraZeneca sees new HQ sticker price gyrate to $1.28B
AstraZeneca may have come a long ways in changing its fortunes on the R&D side of the business, but CEO Pascal Soriot’s 8-year-old dream of building a global Mecca for the company in Cambridge, UK continues to be bedeviled by cost overruns and an uncertain deadline.
The Times is reporting that the pharma giant now expects to spend £1 billion pounds — $1.28 billion — to complete the new headquarters, which the company blueprinted soon after Soriot’s arrival on the job in 2012. Initially, the company laid out a £330 million budget and a 2016 completion date.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.